A characterization of ABL-101 as a potential tracer for clinical fluorine-19 MRI.

Details

Ressource 1Download: Darçot_ABL101charMRI_NMRBiomed2019.pdf (1274.39 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_F9103E2AE976
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A characterization of ABL-101 as a potential tracer for clinical fluorine-19 MRI.
Journal
NMR in biomedicine
Author(s)
Darçot E., Colotti R., Brennan D., Deuchar G.A., Santosh C., van Heeswijk R.B.
ISSN
1099-1492 (Electronic)
ISSN-L
0952-3480
Publication state
Published
Issued date
01/2020
Peer-reviewed
Oui
Volume
33
Number
1
Pages
e4212
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The two main challenges that prevent the translation of fluorine-19 ( <sup>19</sup> F) MRI for inflammation monitoring or cell tracking into clinical practice are (i) the relatively low signal-to-noise ratio generated by the injected perfluorocarbon (PFC), which necessitates long scan times, and (ii) the need for regulatory approval and a high biocompatibility of PFCs that are also suitable for MRI. ABL-101, an emulsion of perfluoro(t-butylcyclohexane), is a third-generation PFC that is already used in clinical trials, but has not yet been used for <sup>19</sup> F MRI. The objective of this study was therefore to assess the performance of ABL-101 as a <sup>19</sup> F MRI tracer. At magnetic field strengths of 3, 9.4 and 14.1 T, the CF <sub>3</sub> groups of ABL-101 generated a large well-separated singlet with T <sub>2</sub> /T <sub>1</sub> ratios of >0.27, >0.14 and > 0.05, respectively. All relaxation times decreased with the increase in magnetic field strength. The detection limit of ABL-101 in a 0.25 mm <sup>3</sup> voxel at 3 T, 37°C and with a 3-minute acquisition time was 7.21mM. After intravenous injection, the clearance half-lives of the ABL-101 <sup>19</sup> F MR signal in mouse (n = 3) spleen and liver were 6.85 ± 0.45 and 3.20 ± 0.35 days, respectively. These results demonstrate that ABL-101 has <sup>19</sup> F MR characteristics that are similar to those of PFCs developed specifically for MRI, while it has clearance half-lives similar to PFCs that have previously been used in large doses in non-MRI clinical trials. Overall, ABL-101 is thus a very promising candidate tracer for future clinical trials that use <sup>19</sup> F MRI for cell tracking or the monitoring of inflammation.
Keywords
Spectroscopy, Molecular Medicine, Radiology Nuclear Medicine and imaging, biocompatibility, clearance half-life, detection limit, fluorine-19 MRI, perfluorocarbon, tracer
Pubmed
Web of science
Open Access
Yes
Funding(s)
Swiss National Science Foundation / 32003B_182615
Swiss National Science Foundation / PZ00P3_154719
Create date
21/11/2019 15:45
Last modification date
12/01/2020 7:20
Usage data